Drug intelligence / Profile preview

NSC 95397

Development stage
Preclinical
Lead developer
National Cancer Institute
Modality
Small Molecules
01

Overview

NSC 95397 is a quinone-based small molecule that acts as a potent inhibitor of dual-specificity phosphatases (DUSPs), most notably the Cdc25 family (Cdc25A, B, and C) and mitogen-activated protein kinase phosphatase-1 (MKP-1/DUSP1). By inhibiting these phosphatases, it prevents the dephosphorylation of their substrates, such as cyclin-dependent kinases (Cdks) and mitogen-activated protein kinases (MAPKs) like ERK1/2, thereby inducing cell cycle arrest (typically at G2/M) and apoptosis. It has been extensively studied in various cancer models, including neuroendocrine tumors, colon cancer, and breast cancer. Additionally, NSC 95397 has been identified as an inhibitor of protein arginine deiminases (PADs) and can covalently modify S100A4, disrupting its interaction with myosin-IIA. However, its utility as a drug candidate is complicated by its activity as a redox cycling compound that generates reactive oxygen species (ROS).

Other names
2,3-bis(2-hydroxyethylsulfanyl)-1,4-naphthoquinone2,3-bis(2-hydroxyethylthio)-1,4-naphthoquinone
02

Targets

CDC25 (CDC25 phosphatase family)CTBP1 (C-terminal-binding protein 1)DUSP6 (Dual specificity protein phosphatase 6)DUSP1CDC25A (Cell division cycle 25A phosphatase)CDC25B (Cell division cycle 25B phosphatase)CDC25C (Cell division cycle 25C phosphatase)

Beyond the preview

Go deeper on NSC 95397.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSC 95397.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call